Literature DB >> 25344147

Imaging caspase-3 activation as a marker of apoptosis-targeted treatment response in cancer.

Delphine L Chen1, Jacquelyn T Engle, Elizabeth A Griffin, J Philip Miller, Wenhua Chu, Dong Zhou, Robert H Mach.   

Abstract

PURPOSE: We tested whether positron emission tomography (PET) with the caspase-3-targeted isatin analog [(18)F]WC-4-116 could image caspase-3 activation in response to an apoptosis-inducing anticancer therapy. PROCEDURES: [(18)F]WC-4-116 uptake was determined in etoposide-treated EL4 cells. Biodistribution studies with [(18)F]WC-4-116 and [(18)F]ICMT-18, a non-caspase-3-targeted tracer, as well as [(18)F]WC-4-116 microPET imaging assessed responses in Colo205 tumor-bearing mice treated with death receptor 5 (DR5)-targeted agonist antibodies. Immunohistochemical staining and enzyme assays confirmed caspase-3 activation. Two-way analysis of variance or Student's t test assessed for treatment-related changes in tracer uptake.
RESULTS: [(18)F]WC-4-116 increased 8 ± 2 fold in etoposide-treated cells. The [(18)F]WC-4-116 % ID/g also increased significantly in tumors with high caspase-3 enzyme activity (p < 0.05). [(18)F]ICMT-18 tumor uptake did not differ in tumors with high or low caspase-3 enzyme activity.
CONCLUSIONS: [(18)F]WC-4-116 uptake in vivo reflects increased caspase-3 activation and may be useful for detecting caspase-3-mediated apoptosis treatment responses in cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25344147      PMCID: PMC4874215          DOI: 10.1007/s11307-014-0802-8

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  32 in total

1.  Synthesis, 18F-radiolabeling, and in vivo biodistribution studies of N-fluorohydroxybutyl isatin sulfonamides using positron emission tomography.

Authors:  Panupun Limpachayaporn; Stefan Wagner; Klaus Kopka; Sven Hermann; Michael Schäfers; Günter Haufe
Journal:  J Med Chem       Date:  2013-05-29       Impact factor: 7.446

Review 2.  Senescence, apoptosis and therapy--cutting the lifelines of cancer.

Authors:  Clemens A Schmitt
Journal:  Nat Rev Cancer       Date:  2003-04       Impact factor: 60.716

3.  Synthesis and evaluation of isatin analogs as caspase-3 inhibitors: introduction of a hydrophilic group increases potency in a whole cell assay.

Authors:  Wenhua Chu; Justin Rothfuss; Dong Zhou; Robert H Mach
Journal:  Bioorg Med Chem Lett       Date:  2011-04-15       Impact factor: 2.823

4.  The nonpeptidyl caspase binding radioligand (S)-1-(4-(2-[18F]Fluoroethoxy)-benzyl)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent.

Authors:  A Faust; S Wagner; M P Law; S Hermann; U Schnöckel; P Keul; O Schober; M Schäfers; B Levkau; K Kopka
Journal:  Q J Nucl Med Mol Imaging       Date:  2007-03       Impact factor: 2.346

5.  Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).

Authors:  Andres Forero-Torres; Jatin Shah; Tina Wood; James Posey; Ronda Carlisle; Catherine Copigneaux; Feng Roger Luo; Slawomir Wojtowicz-Praga; Ivor Percent; Mansoor Saleh
Journal:  Cancer Biother Radiopharm       Date:  2010-02       Impact factor: 3.099

6.  Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types.

Authors:  Paula J Kaplan-Lefko; Jonathan D Graves; Stephen J Zoog; Yang Pan; Jason Wall; Daniel G Branstetter; Jodi Moriguchi; Angela Coxon; Justin N Huard; Ren Xu; Matthew L Peach; Gloria Juan; Stephen Kaufman; Qing Chen; Allison Bianchi; Jennifer J Kordich; Mark Ma; Ian N Foltz; Brian C Gliniak
Journal:  Cancer Biol Ther       Date:  2010-04-20       Impact factor: 4.742

7.  Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fluoropropyl)-4-methyl-pyridin-2-amine as a potential PET tracer for inducible nitric oxide synthase.

Authors:  Dong Zhou; Hsiaoju Lee; Justin M Rothfuss; Delphine L Chen; Datta E Ponde; Michael J Welch; Robert H Mach
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

8.  Isatin sulfonamide analogs containing a Michael addition acceptor: a new class of caspase 3/7 inhibitors.

Authors:  Wenhua Chu; Justin Rothfuss; André d'Avignon; Chenbo Zeng; Dong Zhou; Richard S Hotchkiss; Robert H Mach
Journal:  J Med Chem       Date:  2007-06-23       Impact factor: 7.446

9.  99mTc-HYNIC-annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibody.

Authors:  Francis G Blankenberg; Judy Kalinyak; Liping Liu; Maya Koike; Danye Cheng; Michael L Goris; Allan Green; Jean-Luc Vanderheyden; David C Tong; Midori Anne Yenari
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-14       Impact factor: 9.236

10.  Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide.

Authors:  Quang-Dé Nguyen; Graham Smith; Matthias Glaser; Meg Perumal; Erik Arstad; Eric O Aboagye
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-03       Impact factor: 11.205

View more
  16 in total

Review 1.  Development of Companion Diagnostics.

Authors:  David A Mankoff; Christine E Edmonds; Michael D Farwell; Daniel A Pryma
Journal:  Semin Nucl Med       Date:  2016-01       Impact factor: 4.446

2.  Evaluation of [18F]CP18 as a Substrate-Based Apoptosis Imaging Agent for the Assessment of Early Treatment Response in Oncology.

Authors:  Sara Rapic; Christel Vangestel; Filipe Elvas; Jeroen Verhaeghe; Tim Van den Wyngaert; Leonie Wyffels; Patrick Pauwels; Steven Staelens; Sigrid Stroobants
Journal:  Mol Imaging Biol       Date:  2017-08       Impact factor: 3.488

3.  In Vivo Evaluation of Radiofluorinated Caspase-3/7 Inhibitors as Radiotracers for Apoptosis Imaging and Comparison with [18F]ML-10 in a Stroke Model in the Rat.

Authors:  Marie Médoc; Martine Dhilly; Lidia Matesic; Jérôme Toutain; Anwen M Krause-Heuer; Jérôme Delamare; Benjamin H Fraser; Omar Touzani; Louisa Barré; Ivan Greguric; Franck Sobrio
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

Review 4.  Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer.

Authors:  Tsz-Ying Lau; Hiu-Yee Kwan
Journal:  Mar Drugs       Date:  2022-05-30       Impact factor: 6.085

5.  PET imaging of in vivo caspase-3/7 activity following myocardial ischemia-reperfusion injury with the radiolabeled isatin sulfonamide analogue [(18)F]WC-4-116.

Authors:  Arun K Thukkani; Kooresh I Shoghi; Dong Zhou; Jinbin Xu; Wenhua Chu; Eric Novak; Delphine L Chen; Robert J Gropler; Robert H Mach
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-04-24

6.  A histone H1-binding-aptide-based apoptosis imaging probe for monitoring tumor responses to cancer therapy.

Authors:  Yonghyun Lee; Sunghyun Kim; Daejin Kim; Sangyong Jon
Journal:  Medchemcomm       Date:  2017-01-05       Impact factor: 3.597

7.  Antitumor Effect of Hyperoside Loaded in Charge Reversed and Mitochondria-Targeted Liposomes.

Authors:  Yufei Feng; Guozhao Qin; Shuyuan Chang; Zhongxu Jing; Yanyan Zhang; Yanhong Wang
Journal:  Int J Nanomedicine       Date:  2021-04-28

Review 8.  Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT.

Authors:  Brian P Rempel; Eric W Price; Christopher P Phenix
Journal:  Mol Imaging       Date:  2017 Jan-Dec       Impact factor: 4.488

Review 9.  Avenues to molecular imaging of dying cells: Focus on cancer.

Authors:  Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Med Res Rev       Date:  2018-03-12       Impact factor: 12.944

10.  Pro-BDNF Contributes to Hypoxia/Reoxygenation Injury in Myocardial Microvascular Endothelial Cells: Roles of Receptors p75NTR and Sortilin and Activation of JNK and Caspase 3.

Authors:  Fei Yu; Yuezhu Liu; Junmei Xu
Journal:  Oxid Med Cell Longev       Date:  2018-06-26       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.